Human CD96/TACTILE Protein

产品信息(Product Info)
表达区间及表达系统(Source)

Recombinant Human CD96/TACTILE Protein is expressed from Expi293 with mFc tag at the C-terminal. It contains Val22-Met503.[Accession | P40200-2]

分子量大小(Molecular Weight)

The protein has a predicted MW of 79.8 kDa. Due to glycosylation, the protein migrates to 120-160 kDa based on Tris-Bis PAGE result.

内毒素(Endotoxin)

Less than 1EU per μg by the LAL method.

纯度(Purity)

> 95% as determined by Tris-Bis PAGE
> 95% as determined by HPLC

制剂(Formulation)

Supplied as 0.22μm filtered solution in PBS (pH 7.4). Please dilute to the desired concentration according to the concentration of the solution shown on the product label.

存储(Storage)

Valid for 12 months from date of receipt when stored at -80°C.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please do not repeated freeze-thaw cycles.

产品数据(Assay Data)
Tris-Bis PAGE

Human CD96 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

ELISA Data

Immobilized Human CD96, mFc Tag at 5μg/ml (100μl/Well) on the plate. Dose response curve for Human CD155, hFc Tag with the EC50 of 0.21μg/ml determined by ELISA.

ELISA Data

Immobilized Human CD96, mFc Tag at 2μg/ml (100μl/Well) on the plate. Dose response curve for Anti-CD96 Antibody, hFc Tag with the EC50 of 25.9ng/ml determined by ELISA.

背景(Background)

The receptors CD96 and TIGIT are expressed on the surface of T and natural killer (NK) cells, and recent studies suggest both play important inhibitory roles in immune function. CD96 has been shown to modulate immune cell activity in mice, with Cd96-/- mice displaying hypersensitive NK-cell responses to immune challenge and significant tumor resistance. The counterbalance between the putative inhibitory CD96 and TIGIT receptors and the activating receptor, CD226, offers unique strategies for immuno-oncology drug development.

分子别名(Synonyms)

CD96 molecule; CD96; DKFZp667E2122; TACTILE

文献(References)

(1) Blake SJ, Dougall WC, Miles JJ, Teng MW, Smyth MJ. Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy. Clin Cancer Res. 2016 Nov 1;22(21):5183-5188. doi: 10.1158/1078-0432.CCR-16-0933. Epub 2016 Sep 12. PMID: 27620276.

恺佧生物科技(上海)有限公司
电话:400-614-0008
地址:上海市浦江高科技园新骏环路188号8A区四楼
在线留言